This inventor holds 8 USPTO granted patents and 1 published patent application and 6 EPO patents. Top assignee: Janssen Pharmaceutica Nv. Active years: 2014-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Madrid, ES (2014)
- Toledo, ES (2018 - 2020)
Company Filing History:
Years Active: 2014-2020
Title: The Innovative Mind of Sergio-Alvar Alonso-de Diego
Introduction
Sergio-Alvar Alonso-de Diego, based in Toledo, Spain, is a prominent inventor known for his significant contributions to pharmaceutical innovation. With a remarkable portfolio of eight patents, he has made strides in the field of metabotropic glutamate receptors, particularly through his work at Janssen Pharmaceutica.
Latest Patents
Among his latest patents are groundbreaking inventions related to substituted 6,7-dihydropyrazolo[1,5-a]pyrazines, which serve as negative allosteric modulators of mGluR2 receptors. The first patent describes novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives that target mGluR2, leading to potential new treatments for various disorders. The associated pharmaceutical compositions, preparation processes, and application methods are critical for advancing therapeutic options in this area. Another related patent also details similar compounds and their applications as negative allosteric modulators of mGluR2, strengthening the utility of these inventions in pharmaceutical developments.
Career Highlights
Sergio has dedicated his career to exploring innovative solutions in pharmacology. He has successfully combined his expertise in medicinal chemistry and pharmacology, resulting in critical advancements that enhance our understanding of neurological conditions and their treatments. His role at Janssen Pharmaceutica has positioned him at the forefront of pharmaceutical research and development.
Collaborations
During his career, Sergio has had the opportunity to collaborate with esteemed colleagues, including Michiel Luc Maria Van Gool and Óscar Delgado-González. These collaborations have fostered a dynamic research environment, enabling the exchange of ideas that leads to innovative solutions and advancements in their respective fields.
Conclusion
Sergio-Alvar Alonso-de Diego exemplifies the spirit of innovation and dedication within the pharmaceutical industry. His contributions, particularly in the realm of mGluR2 receptor modulators, signify the ongoing importance of inventors in the advancement of medical science. His work not only enhances therapeutic options but also showcases the collaborative nature of research, driving progress in health and medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile